FBLG on Nasdaq
FibroBiologics, Inc.
American pharmaceutical preparations company based in Houston. Summary from the record
Price unavailable
Last updated Oct 19, 2026.
Overview
- TickerFBLG on Nasdaq2
- IndustryPharmaceutical Preparations2
- HeadquartersHouston, United States2
- Incorporated inDE3
- Business address9350 Kirby Drive, Suite 300, Houston, Tx 770543
- Filer category, Emerging growth company3
- Legal formCorporation2
- LEI5493000KQEGHXVWRMZ922
- StatusActive2
- LEI statusLapsed (not renewed)2
- Registered addressC/O THE CORPORATION TRUST COMPANY, 19801 Wilmington, United States2
- Registered withDivision of Corporations, Department of State, 64710552
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and development | $7.4M | $4.5M |
| General, administrative and other | $9.2M | $9.2M |
| Total operating expenses | $16.6M | $13.7M |
| Loss from operations | -$16.6M | -$13.7M |
| Change in fair value of warrant liability | $0 | $5.4M |
| Change in fair value of forward contract liability | $0 | -$417.0K |
| Change in fair value of SEPA put option liability | $352.0K | -$460.0K |
| Change in fair value of convertible debt | -$1.8M | $232.0K |
| Commitment fee expenses | $0 | -$2.2M |
| Placement agent and tail fee expenses | $0 | -$1.4M |
| Other income/(expense) | -$619.0K | $32.0K |
| Gain on termination of warrant and commitment fee liabilities | $0 | $1.2M |
| Interest income | $247.0K | $251.0K |
| Interest expense | -$204.0K | -$20.0K |
| Total other income/(expense) | -$2.0M | $2.6M |
| Net loss | -$18.6M | -$11.2M |
| Net loss per share, basic | -$0.42 | -$0.34 |
| Net loss per share, diluted | -$0.42 | -$0.34 |
| Weighted-average shares outstanding, basic | 44.7M shares | 32.9M shares |
| Weighted-average shares outstanding, diluted | 44.7M shares | 32.9M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $4.9M | $14.0M | ||
| Prepaid expenses | $1.5M | $225.0K | ||
| Other current assets | $0 | $18.0K | ||
| Total current assets | $6.3M | $14.2M | ||
| Property and equipment, net | $842.0K | $824.0K | ||
| Operating lease right-of-use asset, net | $2.4M | $1.4M | ||
| Other assets | $48.0K | $0 | ||
| Total assets | $9.6M | $16.4M | ||
| Accounts payable and accrued expenses | $945.0K | $2.7M | ||
| Operating lease liability, short-term | $706.0K | $401.0K | ||
| SEPA put option liability | $108.0K | $460.0K | ||
| Short-term convertible debt | $0 | $9.2M | ||
| Total current liabilities | $1.8M | $12.7M | ||
| Operating lease liability, long-term | $1.7M | $984.0K | ||
| Total liabilities | $3.5M | $13.7M | ||
| Preferred Stock, value | $0 | $0 | ||
| Voting Common Stock, $0.00001 par value; 300,000,000 shares and 100,000,000 shares authorized as of December 31, 2025 and 2024, respectively; 66,519,722 shares and 35,085,718 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $1.0K | $0 | ||
| Additional paid-in capital | $60.3M | $38.3M | ||
| Accumulated deficit | -$54.2M | -$35.5M | ||
| Total stockholders equity | $6.2M | $2.7M | $1.3M | |
| Total liabilities and stockholders equity | $9.6M | $16.4M | ||
| Preferred stock, par value | $0.00 | $0.00 | ||
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | ||
| Common stock, par value | $0.00 | |||
| Common stock, shares authorized | 300.0M shares | 100.0M shares | 100.0M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $4.9M | $14.0M | ||
| Prepaid expenses | $1.5M | $225.0K | ||
| Other current assets | $0 | $18.0K | ||
| Total current assets | $6.3M | $14.2M | ||
| Property and equipment, net | $842.0K | $824.0K | ||
| Operating lease right-of-use asset, net | $2.4M | $1.4M | ||
| Other assets | $48.0K | $0 | ||
| Total assets | $9.6M | $16.4M | ||
| Accounts payable and accrued expenses | $945.0K | $2.7M | ||
| Operating lease liability, short-term | $706.0K | $401.0K | ||
| SEPA put option liability | $108.0K | $460.0K | ||
| Short-term convertible debt | $0 | $9.2M | ||
| Total current liabilities | $1.8M | $12.7M | ||
| Operating lease liability, long-term | $1.7M | $984.0K | ||
| Total liabilities | $3.5M | $13.7M | ||
| Preferred Stock, value | $0 | $0 | ||
| Voting Common Stock, $0.00001 par value; 300,000,000 shares and 100,000,000 shares authorized as of December 31, 2025 and 2024, respectively; 66,519,722 shares and 35,085,718 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $1.0K | $0 | ||
| Additional paid-in capital | $60.3M | $38.3M | ||
| Accumulated deficit | -$54.2M | -$35.5M | ||
| Total stockholders equity | $6.2M | $2.7M | $1.3M | |
| Total liabilities and stockholders equity | $9.6M | $16.4M | ||
| Preferred stock, par value | $0.00 | $0.00 | ||
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | ||
| Common stock, par value | $0.00 | |||
| Common stock, shares authorized | 300.0M shares | 100.0M shares | 100.0M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net Income (Loss) | -$18.6M | -$11.2M |
| Change in fair value of warrant liability | $0 | -$5.4M |
| Change in fair value of forward contract liability | $0 | $417.0K |
| Change in fair value of SEPA put option liability | -$352.0K | $460.0K |
| Change in fair value of convertible debt | $1.8M | -$232.0K |
| Commitment fee expense | $0 | $1.9M |
| Gain on termination of warrant and commitment fee liabilities | $0 | -$1.2M |
| Non-cash discount on convertible debt | $625.0K | $0 |
| Stock-based compensation expense | $2.7M | $2.2M |
| Amortization of operating lease right-of-use asset | $588.0K | $416.0K |
| Depreciation expense | $244.0K | $157.0K |
| Prepaid expenses | -$1.2M | -$189.0K |
| Accounts payable and accrued expenses | -$1.5M | $1.3M |
| Other current assets | $18.0K | -$2.0K |
| Other assets | -$48.0K | $0 |
| Payable to Parent | $0 | -$141.0K |
| Operating lease liability | -$550.0K | -$362.0K |
| Net cash used in operating activities | -$16.4M | -$11.9M |
| Purchases of property and equipment | -$262.0K | -$184.0K |
| Net cash used in investing activities | -$262.0K | -$184.0K |
| Proceeds from short-term convertible debt | $4.4M | $9.4M |
| Proceeds from short-term borrowing | $0 | $574.0K |
| Repayments of short-term borrowing | $0 | -$574.0K |
| Repayments of short-term convertible debt | -$3.4M | $0 |
| Proceeds from issuance of common stock, net of direct costs | $6.6M | $7.5M |
| Net cash provided by financing activities | $7.6M | $16.9M |
| Net decrease in cash and cash equivalents | -$9.1M | $4.8M |
| Cash paid for income taxes | $0 | $0 |
| Cash paid for interest | $204.0K | $20.0K |
| Settlement of forward contract liability for sale of shares to GEM pursuant to Draw Down and Closing Notices | $0 | $417.0K |
| Issuance of Voting Common Stock to terminate Share Subscription Agreement | $0 | $2.5M |
| Additions to accounts payable and accrued expenses for purchases of property and equipment | $0 | $17.0K |
| Right of use asset obtained in exchange for operating lease liability | $1.6M | $0 |
| Issuance of Voting Common Stock for commitment fee payable | $250.0K | $0 |
| Conversion of Short-term convertible note payable into shares of common stock | $12.5M | $0 |
No quarter-by-quarter statement was filed.
Leadership
Who has led FibroBiologics, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
2025
- Chief executive officerPete O'Heeron Feb 8, 2024 to now9
- Chief financial officerJason Davis Jun 10, 2025 to now10
- Chief financial officerMark C. Andersen Feb 7, 2024 to Aug 13, 202411
Board members and other officers (9)
- Chief Scientific OfficerHamid Khoja Feb 8, 2024 to now12
- Board memberKathleen Hallisey Rubins Jul 16, 2026 to now13
- Board memberLeigh Steinberg Sep 1, 2026 to now14
- Board memberRobert Hoffman Feb 7, 2024 to now15
- Board memberPete O'Heeron Feb 8, 2024 to now9
- Board memberMatthew Link Feb 13, 2024 to now16
- Board memberStacy Ann Coen Feb 13, 2024 to now17
- Board memberVictoria Ninon Olivia Niklas Feb 15, 2024 to now18
- General counselRuben A. Garcia Mar 6, 2024 to now19
Named in SEC Form D filings
People the company listed in its private-offering notices.
- DirectorRichard C. Cilento named Dec 3, 2025 to Sep 16, 202620
Former names
- FibroBiologics Inc.Jan 31, 2023 to Feb 6, 20243
Timeline
Filings
239 filings to the SEC since October 2021: 4 annual reports, 8 quarterly reports, 48 major events, 57 insider forms, 7 large holders, 6 private raises, 109 other. The latest 20:
- Oct 13, 2026D EDGAR
- Oct 13, 2026POS AM EDGAR
- Oct 13, 2026POS AM EDGAR
- Oct 8, 20268-K EDGAR
- Sep 18, 20268-K EDGAR
- Sep 17, 2026SCHEDULE 13D EDGAR
- Sep 16, 2026D EDGAR
- Sep 15, 20264 EDGAR
- Sep 15, 20268-K EDGAR
- Sep 9, 2026DEFA14A EDGAR
- Sep 1, 20263 EDGAR
- Aug 24, 20268-K EDGAR
- Aug 14, 2026SCHEDULE 13G EDGAR
- Jul 31, 202610-Q EDGAR
- Jul 31, 2026DEF 14A EDGAR
- Jul 24, 20268-K EDGAR
- Jul 17, 2026PRE 14A EDGAR
- Jul 16, 2026EFFECT EDGAR
- Jul 16, 20263 EDGAR
- Jul 16, 2026424B3 EDGAR
The 239 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
10 open-market trades by officers, directors and large owners since October 2021: 10 buys and 0 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Mar 4, 2026 | Khoja HamidChief Scientific Officer | Buy | 30,000 | $0.38 | $11.4K | Form 4 |
| Mar 4, 2026 | O'HEERON PETECHIEF EXECUTIVE OFFICER | Buy | 15,872 | $0.38 | $6.0K | Form 4 |
| Mar 3, 2026 | O'HEERON PETECHIEF EXECUTIVE OFFICER | Buy | 18,200 | $0.41 | $7.5K | Form 4 |
| Mar 2, 2026 | O'HEERON PETECHIEF EXECUTIVE OFFICER | Buy | 17,428 | $0.35 | $6.1K | Form 4 |
| Mar 2, 2026 | Davis JasonChief Financial Officer | Buy | 70,000 | $0.41 | $28.7K | Form 4 |
| Feb 27, 2026 | GARCIA RUBEN AGeneral Counsel | Buy | 40,000 | $0.33 | $13.2K | Form 4 |
| Dec 11, 2025 | GARCIA RUBEN AGeneral Counsel | Buy | 140,000 | $0.34 | $47.6K | Form 4 |
| May 27, 2025 | Khoja HamidChief Scientific Officer | Buy | 20,000 | $0.84 | $16.8K | Form 4 |
| Aug 12, 2024 | O'HEERON PETECHIEF EXECUTIVE OFFICER | Buy | 8,500 | $1.91 | $16.2K | Form 4 |
| Aug 12, 2024 | Khoja HamidChief Scientific Officer | Buy | 10,000 | $1.90 | $19.0K | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Hamid KhojaSCHEDULE 13D, 1 filing Sep 17, 202621
- ARMISTICE CAPITAL, LLCSCHEDULE 13G, 1 filing Aug 14, 202622
- Lind Global Fund III LPSCHEDULE 13G, 1 filing Apr 9, 202623
- Michael F. NewlinSCHEDULE 13G, 1 filing Jun 6, 202524
- Pete O'HeeronSCHEDULE 13G, 1 filing Feb 12, 202525
- BlackRockSCHEDULE 13G/A, 2 filings Jan 29, 2025 to Jan 30, 202526
Money raised
Private offerings the company reported to the SEC on Form D.
- Sep 15, 2026Raised $500,001 in a private offering of equity Form D: 1 investor so far Form D
- Jun 25, 2026Raised $3 million in a private offering of securities Form D: 1 investor so far Form D
- Dec 14, 2025Raised $1.7 million in a private offering of equity Form D: 4 investors so far Form D
- Nov 24, 2025Raised $1.5 million in a private offering of equity Form D: 4 investors so far Form D
- Nov 18, 2025Raised $4 million in a private offering of equity Form D: 1 investor so far Form D
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Cascade Financial Partners, LLC | 108,828 | $103.1K | 0.0% | +92,400 |
| Fund Evaluation Group, LLC | 51,794 | $49.1K | 0.0% | No change |
| Geode Capital Management, LLC | 30,299 | $28.7K | 0.0% | +690 |
| Vanguard Capital Management LLC | 27,769 | $26.3K | 0.0% | −39,896 |
| Qube Research & Technologies Ltd | 24,313 | $23.0K | 0.0% | New |
| BlackRock, Inc. | 18,238 | $17.3K | 0.0% | −6,409 |
| Barclays PLC | 7,243 | $6.9K | 0.0% | New |
| Vanguard Fiduciary Trust Co | 6,380 | $6.0K | 0.0% | No change |
| Tower Research Capital LLC (TRC) | 4,728 | $4.5K | 0.0% | +4,268 |
| Osaic Holdings, Inc. | 2,404 | $2.3K | 0.0% | +2,250 |
| UBS Group AG | 1,073 | $1.0K | 0.0% | −4,648 |
| Royal Bank Of Canada | 1,522 | $1.0K | 0.0% | +1,336 |
| Islay Capital Management, LLC | 169 | $160 | 0.0% | No change |
| Grove Bank & Trust | 100 | $95 | 0.0% | New |
| Bnp Paribas Financial Markets | 64 | $61 | 0.0% | −2 |
| Allworth Financial LP | 13 | $13 | 0.0% | No change |
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10SEC EDGARJason Davis, Chief financial officer
- 11
- 12
- 13
- 14SEC EDGARLeigh Steinberg, Board member
- 15SEC EDGARRobert Hoffman, Board member
- 16SEC EDGARMatthew Link, Board member
- 17SEC EDGARStacy Ann Coen, Board member
- 18
- 19SEC EDGARRuben A. Garcia, General counsel
- 20
- 21
- 22
- 23
- 24
- 25
- 26